Early relapse after rituximab chemoimmunotherapy

Flora Kiss, Julia Buslig, Istvan Szegedi, Beata Scholtz, Janos Kappelmayer, Csongor Kiss

Research output: Contribution to journalArticle

4 Citations (Scopus)


In relapsed/refractory childhood acute lymphoblastic leukemia (ALL) of the B-cell lineage rituximab, a monoclonal anti-CD20 antibody was used successfully in some cases. We report on a 15-year-old female with relapsed CD20-positive B-cell progenitor ALL treated with rituximab because of positive minimal residual disease signals after chemotherapy, as checked by flow cytometry and real time quantitative-PCR. Rituximab eliminated the CD20-positive subpopulation, but not the more immature leukemic cells. The patient died with fulminant aspergillosis before hematopoietic stem cell transplantation could be performed.

Original languageEnglish
Pages (from-to)372-375
Number of pages4
JournalPediatric Blood and Cancer
Issue number2
Publication statusPublished - Feb 1 2008


  • B-cell progenitor
  • Childhood acute lymphoblastic leukemia
  • Minimal residual disease
  • Rituximab
  • Treatment failure

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Early relapse after rituximab chemoimmunotherapy'. Together they form a unique fingerprint.

  • Cite this